BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 307] [Cited by in F6Publishing: 256] [Article Influence: 19.2] [Reference Citation Analysis]
Number Citing Articles
1 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
2 Ishida N, Tani S, Asai Y, Miyazu T, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. Sci Rep 2022;12:13572. [PMID: 35945329 DOI: 10.1038/s41598-022-17763-2] [Reference Citation Analysis]
3 Kumar S, Pollok R, Goldsmith D. Renal and Urological Disorders Associated With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac140. [PMID: 35942657 DOI: 10.1093/ibd/izac140] [Reference Citation Analysis]
4 Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT, Johnson D, Ng SC, Sharma V, Rubin DT, Gibson PR, Christensen B. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther 2022;56:6-27. [PMID: 35596242 DOI: 10.1111/apt.16952] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
6 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
7 Zeng J, Wang Z, Yang X. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03312-3] [Reference Citation Analysis]
8 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
9 Limdi JK. Editorial commentary on Indian Journal of Gastroenterology-November-December 2021. Indian J Gastroenterol 2022. [PMID: 35076892 DOI: 10.1007/s12664-021-01236-x] [Reference Citation Analysis]
10 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov 2022;3:100071. [PMID: 34988432 DOI: 10.1016/j.crphar.2021.100071] [Reference Citation Analysis]
12 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sud S, Sachdeva S, Puri AS. Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India. Indian J Gastroenterol 2021. [PMID: 34971402 DOI: 10.1007/s12664-021-01185-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
15 Niu W, Dong Y, Fu Z, Lv J, Wang L, Zhang Z, Huo J, Ju J. Effects of molecular weight of chitosan on anti-inflammatory activity and modulation of intestinal microflora in an ulcerative colitis model. Int J Biol Macromol 2021:S0141-8130(21)02422-3. [PMID: 34748786 DOI: 10.1016/j.ijbiomac.2021.11.024] [Reference Citation Analysis]
16 Hishinuma K, Moroi R, Okamoto D, Shimoyama Y, Kuroha M, Shiga H, Kakuta Y, Kinouchi Y, Masamune A. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci. Inflamm Intest Dis 2021;6:154-64. [PMID: 34722645 DOI: 10.1159/000518371] [Reference Citation Analysis]
17 Cokelaere SM, Groen WMGAC, Plomp SGM, de Grauw JC, van Midwoud PM, Weinans HH, van de Lest CHA, Tryfonidou MA, van Weeren PR, Korthagen NM. Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints. Pharmaceutics 2021;13:1438. [PMID: 34575514 DOI: 10.3390/pharmaceutics13091438] [Reference Citation Analysis]
18 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 45.0] [Reference Citation Analysis]
22 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Salem G, Ding K, Sakuraba A, Cohen R. Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review. J Investig Med 2021:jim-2020-001699. [PMID: 33622709 DOI: 10.1136/jim-2020-001699] [Reference Citation Analysis]
24 Li B, Du P, Du Y, Zhao D, Cai Y, Yang Q, Guo Z. Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats. Life Sci 2021;269:119008. [PMID: 33434535 DOI: 10.1016/j.lfs.2020.119008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
25 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Marutani Y, Mizoshita T, Sugiyama T, Togawa S, Katano T, Yamada T, Hirata Y, Kimura Y, Miyaki T, Inoue Y, Suzuki E, Sasaki M, Kataoka H. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. Indian J Gastroenterol 2020;39:565-75. [PMID: 33106991 DOI: 10.1007/s12664-020-01092-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Kucharzik T, Dignaß A, Siegmund B. Aktualisierung der Colitis ulcerosa Leitlinie 2020. Z Gastroenterol 2020;58:1209-32. [DOI: 10.1055/a-1296-3494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
30 Pathak S, Regmi S, Nepal MR, Shrestha P, Choi JU, Yook S, Jeong J. Single-dose intraperitoneal delivery of FK506-encapsulated polymeric microspheres for the alleviation of murine colitis. Journal of Industrial and Engineering Chemistry 2020;91:121-8. [DOI: 10.1016/j.jiec.2020.07.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Heron V, Loftus EV Jr. Nonbiologic Immune Suppression in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:731-8. [PMID: 33121692 DOI: 10.1016/j.gtc.2020.07.003] [Reference Citation Analysis]
32 Wu B, Tong J, Ran Z. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2020;26:24-32. [PMID: 30980713 DOI: 10.1093/ibd/izz068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
33 Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, Miyasaka N. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford) 2020;59:1084-93. [PMID: 31539061 DOI: 10.1093/rheumatology/kez394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
34 Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Reference Citation Analysis]
36 Yamamoto Y, Nakase H, Matsuura M, Maruyama S, Masuda S. CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients. Int J Mol Sci 2020;21:E4347. [PMID: 32570960 DOI: 10.3390/ijms21124347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Levy LC, Coburn ES, Choi S, Holubar SD. The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum. Current Opinion in Gastroenterology 2020;36:265-76. [DOI: 10.1097/mog.0000000000000637] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:949-59. [PMID: 31665288 DOI: 10.1093/ibd/izz244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Liu P, Bian Y, Liu T, Zhong J, Zhong Y, Zhuang S, Liu Z. Huai hua san alleviates dextran sulphate sodium-induced colitis and modulates colonic microbiota. J Ethnopharmacol 2020;259:112944. [PMID: 32387236 DOI: 10.1016/j.jep.2020.112944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Rodríguez-Lago I, Castro-Poceiro J, Fernández-Clotet A, Mesonero F, López-Sanromán A, López-García A, Márquez L, Clos-Parals A, Cañete F, Vicuña M, Nantes Ó, Merino O, Matallana V, Gordillo J, Elorza A, Vicente R, Casanova MJ, Ferreiro-Iglesias R, Pérez-Galindo P, Benítez JM, Taxonera C, García MJ, Martín E, Aguirre U, Gisbert JP; Young GETECCU Group. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:870-9. [PMID: 32181930 DOI: 10.1111/apt.15687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
43 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
44 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
45 Okabayashi S, Kobayashi T, Hibi T. Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? J Anus Rectum Colon 2020;4:1-13. [PMID: 32002471 DOI: 10.23922/jarc.2019-003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
46 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
47 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
48 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
49 Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
50 Regmi S, Pathak S, Nepal MR, Shrestha P, Park J, Kim JO, Yong CS, Choi D, Chang J, Jeong TC, Orive G, Yook S, Jeong J. Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation. Journal of Controlled Release 2019;316:138-49. [DOI: 10.1016/j.jconrel.2019.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
51 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
53 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
54 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
55 Yanagi T, Ushijima K, Koga H, Tomomasa T, Tajiri H, Kunisaki R, Isihige T, Yamada H, Arai K, Yoden A, Aomatsu T, Nagata S, Uchida K, Ohtsuka Y, Shimizu T. Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan. Intest Res 2019;17:476-85. [PMID: 31454858 DOI: 10.5217/ir.2019.00027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens 2019;8:E126. [PMID: 31412603 DOI: 10.3390/pathogens8030126] [Cited by in Crossref: 127] [Cited by in F6Publishing: 113] [Article Influence: 42.3] [Reference Citation Analysis]
57 Wang JJ, Fan YH. Advances in research of tacrolimus for treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(13): 842-850 [DOI: 10.11569/wcjd.v27.i13.842] [Reference Citation Analysis]
58 Wu F, Yang Y, Wang X, Wang Z, Zhang W, Liu Z, Qian Y. A sample processing method for immunoassay of whole blood tacrolimus. Analytical Biochemistry 2019;576:13-9. [DOI: 10.1016/j.ab.2019.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Yamagami H, Nishida Y, Nagami Y, Hosomi S, Yukawa T, Otani K, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis. Rom J Intern Med 2017;55:151-7. [PMID: 28222041 DOI: 10.1515/rjim-2017-0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
60 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
61 Naganuma M. Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases. Immunol Med 2019;42:16-21. [PMID: 31034341 DOI: 10.1080/25785826.2019.1599158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
62 Iida T, Nojima M, Nakase H. Therapeutic Efficacy and Adverse Events of Tacrolimus in Patients with Crohn's Disease: Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64:2945-54. [PMID: 30982208 DOI: 10.1007/s10620-019-05619-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617 [PMID: 30983820 DOI: 10.3748/wjg.v25.i13.1603] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
64 Park YE, Kim TO. Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease. World J Mens Health 2020;38:285-97. [PMID: 30929327 DOI: 10.5534/wjmh.190007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
65 Nishida Y, Hosomi S, Yamagami H, Sugita N, Itani S, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Watanabe T, Fujiwara Y. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS One. 2019;14:e0213505. [PMID: 30845259 DOI: 10.1371/journal.pone.0213505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
66 Suzuki T, Mizoshita T, Tanida S, Sugimura N, Katano T, Nishie H, Kataoka H. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open 2019;3:217-23. [PMID: 31276039 DOI: 10.1002/jgh3.12140] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
68 Okabayashi S, Kobayashi T, Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intest Res 2019;17:218-26. [PMID: 30704156 DOI: 10.5217/ir.2018.00117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
69 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
70 Yamada Y, Ohno Y, Niwa T, Kato-Hayashi H, Hayashi H, Ibuka T, Araki H, Sugiyama T, Shimizu M, Suzuki A. Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis. J Clin Pharm Ther. 2019;44:409-414. [PMID: 30604428 DOI: 10.1111/jcpt.12800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016;50:803-818. [PMID: 27741097 DOI: 10.1097/mcg.0000000000000660] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
73 Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, Stange E, Wehkamp J. Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflamm Intest Dis 2019;3:116-24. [PMID: 30820433 DOI: 10.1159/000493979] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Suzuka T, Kotani T, Takeuchi T, Fujiki Y, Hata K, Yoshida S, Shoda T, Makino S, Arawaka S. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis 2019;22:303-13. [PMID: 30398034 DOI: 10.1111/1756-185X.13414] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
75 Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol 2018;53:1236-44. [PMID: 30353757 DOI: 10.1080/00365521.2018.1511825] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Okabayashi S, Kobayashi T, Hibi T. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflamm Intest Dis 2018;3:25-31. [PMID: 30505839 DOI: 10.1159/000491878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Sato T, Konno J, Sekiguchi A, Yoneki N, Kawano K, Hayashi T, Ogawa Y, Kikitsu A, Aijima T, Hara K, Hara S, Hayashi H, Fuchigami K, Igo N, Takashima Y, Kobayashi Y, Mori M, Yamamoto K, Niwa M, Saiga K, Ichimura E. Long-lasting immunosuppressive effects of tacrolimus-loaded micelle NK61060 in preclinical arthritis and colitis models. Ther Deliv 2018;9:711-29. [PMID: 30277135 DOI: 10.4155/tde-2018-0044] [Reference Citation Analysis]
78 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
79 Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, Wei SC. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019;118:1083-1092. [PMID: 30054112 DOI: 10.1016/j.jfma.2018.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
80 Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018;78:383-94. [PMID: 29332708 DOI: 10.1016/j.jaad.2017.06.043] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
81 Tun GS, Harris A, Lobo AJ. Ulcerative colitis: management in adults, children and young people - concise guidance . Clin Med (Lond) 2017;17:429-33. [PMID: 28974592 DOI: 10.7861/clinmedicine.17-5-429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
82 Henmi Y, Kakimoto K, Inoue T, Nakazawa K, Kubota M, Hara A, Mikami T, Naka Y, Hirata Y, Hirata Y, Sakanaka T, Nouda S, Okada T, Kawakami K, Takeuchi T, Tominaga K, Higuchi K. Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressants. J Clin Biochem Nutr 2018;63:246-51. [PMID: 30487677 DOI: 10.3164/jcbn.18-14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
84 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
85 Onodera M, Endo K, Kakuta Y, Kuroha M, Kimura T, Hiramoto K, Kanazawa Y, Negoro K, Shiga H, Kinouchi Y, Shimosegawa T. ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017;32:1562-1569. [PMID: 28135009 DOI: 10.1111/jgh.13753] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
86 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 207] [Article Influence: 63.0] [Reference Citation Analysis]
87 Saifuddin A, Harris A. Tacrolimus therapy in moderate to subacute ulcerative proctocolitis: a large single-centre cohort study. Frontline Gastroenterol. 2018;9:148-153. [PMID: 29588844 DOI: 10.1136/flgastro-2017-100888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
88 Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017;32:1143-1151. [PMID: 27957761 DOI: 10.1111/jgh.13674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
89 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
90 Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. Dig Dis 2018;36:106-12. [PMID: 29050007 DOI: 10.1159/000481815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
92 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
93 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Mizoshita T, Katano T, Tanida S, Hirano A, Miyaki T, Ozeki K, Suzuki Y, Sugimura N, Kataoka H, Joh T. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore) 2017;96:e7800. [PMID: 28796080 DOI: 10.1097/MD.0000000000007800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
95 Lawrance IC, Baird A, Lightower D, Radford-smith G, Andrews JM, Connor S. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2017;15:1248-55. [DOI: 10.1016/j.cgh.2017.02.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
96 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
97 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
98 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
99 Truffinet O, Martinez-vinson C, Guerriero E, Hugot J, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 2017;64:721-5. [DOI: 10.1097/mpg.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
100 Kawamura H, Matsumoto S, Nakamura N, Miyatani H, Mashima H. Rapid Induction Therapy with Oral Tacrolimus in Elderly Patients with Refractory Ulcerative Colitis Can Easily Lead to Elevated Tacrolimus Concentrations in Blood: A Report of 5 Cases. Am J Case Rep 2017;18:405-9. [PMID: 28411286 DOI: 10.12659/ajcr.903339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
101 Lasa J, Olivera P. Efficacy of tacrolimus for induction of remission in patients with moderate-to-severe ulcerative colitis: A systematic review and meta-analysis. Arq Gastroenterol. 2017;54:167-172. [PMID: 28327826 DOI: 10.1590/s0004-2803.201700000-15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
103 Mallet AL, Bouguen G, Conroy G, Roblin X, Delobel JB, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017;49:280-285. [PMID: 28089625 DOI: 10.1016/j.dld.2016.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
104 Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, Kuwabara S. Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol 2017;24:270-5. [DOI: 10.1111/ene.13189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
105 Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, Boltze J. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 2017;14:146-79. [PMID: 27721455 DOI: 10.1038/cmi.2016.39] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
106 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
107 Xu Y, Dong H, Ge C, Gao Y, Liu H, Li W, Zhang C. CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation. Ann Transl Med 2016;4:301. [PMID: 27668221 DOI: 10.21037/atm.2016.08.25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
108 Asada A, Bamba S, Morita Y, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sugimoto M, Sasaki M, Andoh A. The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus. Dig Liver Dis. 2017;49:24-28. [PMID: 27717793 DOI: 10.1016/j.dld.2016.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
109 Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol 2016;3:e000103. [PMID: 27648296 DOI: 10.1136/bmjgast-2016-000103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
110 Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study. Gastroenterol Res Pract 2016;2016:5956316. [PMID: 27413367 DOI: 10.1155/2016/5956316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Oral pathology in inflammatory bowel disease. World J Gastroenterol 2016; 22(25): 5655-5667 [PMID: 27433081 DOI: 10.3748/wjg.v22.i25.5655] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
113 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
114 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. Aliment Pharmacol Ther 2016;43:1243. [PMID: 27137731 DOI: 10.1111/apt.13602] [Reference Citation Analysis]
115 Laharie D, Poullenot F. Letter: which patient profile for tacrolimus in ulcerative colitis? Aliment Pharmacol Ther 2016;43:1242-3. [PMID: 27137730 DOI: 10.1111/apt.13598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
117 Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med. 2016;12:829-834. [PMID: 27446283 DOI: 10.3892/etm.2016.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
118 Shah ED, Siegel CA, Chong K, Melmed GY. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis 2016;22:933-9. [PMID: 26818417 DOI: 10.1097/MIB.0000000000000680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
120 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
121 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: A retrospective observational study. Aliment Pharmacol Ther. 2016;43:705-716. [PMID: 26762838 DOI: 10.1111/apt.13531] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
122 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
123 Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016;10:484-494. [PMID: 26645641 DOI: 10.1093/ecco-jcc/jjv221] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 6.1] [Reference Citation Analysis]
124 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
125 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
126 Xiao HT, Peng J, Hu DD, Lin CY, Du B, Tsang SW, Lin ZS, Zhang XJ, Lueng FP, Han QB, Bian ZX. Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice. Chin Med 2015;10:29. [PMID: 26464580 DOI: 10.1186/s13020-015-0061-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
127 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
128 Hayashi R, Ueno Y, Tanaka S, Sagami S, Nagai K, Shigemoto N, Uegami S, Shimizu W, Watadani Y, Ohge H, Chayama K. Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy. Case Rep Gastroenterol 2015;9:272-7. [PMID: 26351416 DOI: 10.1159/000438784] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
130 Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis. 2016;10:226-235. [PMID: 26223844 DOI: 10.1093/ecco-jcc/jjv138] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
131 Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflamm Bowel Dis 2014;20:2151-6. [PMID: 25029618 DOI: 10.1097/MIB.0000000000000130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
132 Narula N, Fine M, Colombel J, Marshall JK, Reinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2015;21:1683-94. [DOI: 10.1097/mib.0000000000000350] [Cited by in Crossref: 50] [Cited by in F6Publishing: 18] [Article Influence: 7.1] [Reference Citation Analysis]
133 Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
134 Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13:219-226. [PMID: 26130996 DOI: 10.5217/ir.2015.13.3.219] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
135 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
136 Hiraoka S, Kato J, Moritou Y, Takei D, Inokuchi T, Nakarai A, Takahashi S, Harada K, Okada H, Yamamoto K. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015;15:53. [PMID: 25925267 DOI: 10.1186/s12876-015-0285-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
137 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
138 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
139 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
140 Kawakami K, Inoue T, Murano M, Narabayashi K, Nouda S, Ishida K, Abe Y, Nogami K, Hida N, Yamagami H, Watanabe K, Umegaki E, Nakamura S, Arakawa T, Higuchi K. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015; 21(6): 1880-1886 [PMID: 25684955 DOI: 10.3748/wjg.v21.i6.1880] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
141 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
144 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 13.9] [Reference Citation Analysis]
146 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
147 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Boschetti G, Nancey S, Moussata D, Stefanescu C, Roblin X, Chauvenet M, Stroeymeyt K, Bouhnik Y, Flourié B. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Digestive and Liver Disease 2014;46:875-80. [DOI: 10.1016/j.dld.2014.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
149 Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-1563. [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 106] [Article Influence: 15.9] [Reference Citation Analysis]
150 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
151 Stacey R, Thomas L. Medical management of Crohn's disease and ulcerative colitis. Surgery (Oxford) 2014;32:418-20. [DOI: 10.1016/j.mpsur.2014.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
153 Nagayama K, Takedatsu H, Mitsuyama K, Yamasaki H, Kuwaki K, Yoshioka S, Kobayashi T, Yamauchi R, Kakuma T, Sata M. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients. Ther Apher Dial 2014;18:244-51. [PMID: 24965290 DOI: 10.1111/1744-9987.12211] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
154 Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427-37. [PMID: 24908178 DOI: 10.1016/j.crohns.2014.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
155 Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 2014;15:1659-70. [DOI: 10.1517/14656566.2014.925445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
156 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
157 Rietdijk ST, D'Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol 2014;7:423-30. [PMID: 24802046 DOI: 10.1586/17512433.2014.911084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Farkas K, Molnár T, Szepes Z. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:695-702. [DOI: 10.1586/17474124.2014.909726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
160 Gray FL, Turner CG, Zurakowski D, Bousvaros A, Linden BC, Shamberger RC, Lillehei CW. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg. 2013;48:1540-1545. [PMID: 23895969 DOI: 10.1016/j.jpedsurg.2013.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
161 Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 2013;23:563-85. [PMID: 23922006 DOI: 10.1097/FPC.0b013e328364db84] [Cited by in Crossref: 119] [Cited by in F6Publishing: 46] [Article Influence: 14.9] [Reference Citation Analysis]
162 Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014; 20(5): 1248-1258 [PMID: 24574799 DOI: 10.3748/wjg.v20.i5.1248] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
163 Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013;19:1490-1498. [PMID: 23615528 DOI: 10.1097/mib.0b013e318281f362] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
164 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
165 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
166 Navas-lópez V, Blasco Alonso J, Serrano Nieto M, Girón Fernández-crehuet F, Argos Rodriguez M, Sierra Salinas C. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. Journal of Crohn's and Colitis 2014;8:64-9. [DOI: 10.1016/j.crohns.2013.03.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
167 Hirai F, Takatsu N, Yano Y, Satou Y, Takahashi H, Ishikawa S, Tsurumi K, Hisabe T, Matsui T. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus: CYP3A5 gene and ulcerative colitis. J Gastroenterol Hepatol 2014;29:60-6. [DOI: 10.1111/jgh.12361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
168 Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
169 Tsukamoto H, Tanida S, Mizoshita T, Ozeki K, Ebi M, Shimura T, Mori Y, Kataoka H, Kamiya T, Joh T. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. Eur J Gastroenterol Hepatol. 2013;25:714-718. [PMID: 23411870 DOI: 10.1097/meg.0b013e32835eb999] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
170 Uchino M, Ikeuchi H, Matsuoka H, Bando T, Hida N, Nakamura S, Takesue Y, Tomita N. Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum. 2013;56:1166-1173. [PMID: 24022534 DOI: 10.1097/dcr.0b013e31829ebd83] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
171 Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19:418-422. [PMID: 22605673 DOI: 10.1002/ibd.23027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
172 Hirai F, Takatsu N, Matsui T. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2013;37:501. [PMID: 23336690 DOI: 10.1111/apt.12203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
173 Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012;18:584-91. [PMID: 22009735 DOI: 10.1002/ibd.21847] [Cited by in Crossref: 85] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
174 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
175 Nakane S, Fujita K, Shibuta Y, Matsui N, Harada M, Urushihara R, Nishida Y, Izumi Y, Kaji R. Successful treatment of stiff person syndrome with sequential use of tacrolimus. J Neurol Neurosurg Psychiatry 2013;84:1177-80. [DOI: 10.1136/jnnp-2013-305425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
176 Miyoshi J, Matsuoka K, Inoue N, Hisamatsu T, Ichikawa R, Yajima T, Okamoto S, Naganuma M, Sato T, Kanai T, Ogata H, Iwao Y, Hibi T. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013;7:e609-e614. [PMID: 23680174 DOI: 10.1016/j.crohns.2013.04.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
177 Fukunaga K, Ohda Y, Hida N, Iimuro M, Yokoyama Y, Kamikozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808-1815. [PMID: 22775479 DOI: 10.1111/j.1440-1746.2012.07215.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
178 Jørgensen KK, Lindström L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM. Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:517-23. [DOI: 10.1016/j.cgh.2012.12.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
179 Landy J, Wahed M, Peake ST, Hussein M, Ng SC, Lindsay JO, Hart AL. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres. J Crohns Colitis. 2013;7:e516-e521. [PMID: 23623737 DOI: 10.1016/j.crohns.2013.03.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
180 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol 2013;2013:304894. [PMID: 23691335 DOI: 10.1155/2013/304894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
181 Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
182 Landy J, Hart AL. Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2013;37:493. [PMID: 23336680 DOI: 10.1111/apt.12178] [Reference Citation Analysis]
183 Schmidt KJ, Fellermann K, Büning J. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. Aliment Pharmacol Ther 2013;37:502. [PMID: 23336691 DOI: 10.1111/apt.12214] [Reference Citation Analysis]
184 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
186 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
187 Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther. 2013;137:283-297. [PMID: 23103332 DOI: 10.1016/j.pharmthera.2012.10.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
188 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
189 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
190 Hidaka M, Nakamura M, Ohmichi Y, Itoh J, Fukuzawa K, Masuko T, Yagi H. Involvement of intestinal intraepithelial lymphocytes in turnover of intestinal epithelial cells: Morphological and functional alterations due to daily administration of FK506. Cellular Immunology 2012;279:124-33. [DOI: 10.1016/j.cellimm.2012.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
191 Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. World J Gastroenterol 2012; 18(29): 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
192 Hirano K, Naito T, Mino Y, Takayama T, Ozono S, Kawakami J. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients. Clin Chim Acta 2012;414:120-4. [PMID: 22889968 DOI: 10.1016/j.cca.2012.07.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
193 Atreya R, Neumann H, Neurath MF. [Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?]. MMW Fortschr Med 2012;154:76-8. [PMID: 22957389 DOI: 10.1007/s15006-012-0934-1] [Reference Citation Analysis]
194 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
195 Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis. 2013;7:e49-e54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
196 Annunziata ML, Hanauer SB. Calcineurin inhibition in severe ulcerative colitis: Lost in translation?: . Inflammatory Bowel Diseases 2012;18:809-11. [DOI: 10.1002/ibd.21848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
197 Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012;143:62-69.e4. [PMID: 22504093 DOI: 10.1053/j.gastro.2012.04.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
198 Bamba S, Andoh A, Imaeda H, Ban H, Kobori A, Mochizuki Y, Shioya M, Nishimura T, Inatomi O, Sasaki M, Saitoh Y, Tsujikawa T, Fujiyama Y. Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med 2012;4:99-104. [PMID: 23060930 DOI: 10.3892/etm.2012.545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
199 Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235-246. [PMID: 22306429 DOI: 10.1016/j.jconrel.2012.01.028] [Cited by in Crossref: 141] [Cited by in F6Publishing: 128] [Article Influence: 14.1] [Reference Citation Analysis]
200 Büning J, Fellermann K. [Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. Internist (Berl) 2011;52:833-40. [PMID: 21660632 DOI: 10.1007/s00108-010-2797-9] [Reference Citation Analysis]
201 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
203 Pan A, Schlup M, Lubcke R, Schultz M. Fulminant ulcerative colitis despite maximal immunosuppression following liver transplantation: A case report and literature review. Journal of Crohn's and Colitis 2011;5:465-8. [DOI: 10.1016/j.crohns.2011.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
204 Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, Koyanagi K, Hibi T. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803-808. [PMID: 21887732 DOI: 10.1002/ibd.21853] [Cited by in Crossref: 144] [Cited by in F6Publishing: 126] [Article Influence: 13.1] [Reference Citation Analysis]
205 Okada Y, Maeda N, Takakura S, Miyata K, Koshiba M. Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis. Inflamm Res 2011;60:1049-59. [PMID: 21830095 DOI: 10.1007/s00011-011-0366-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
206 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
207 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
208 Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol. 2009;2:99-108. [PMID: 21180538 DOI: 10.1177/1756283x09102329] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
209 Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol. 2011;2011:194324. [PMID: 21991497 DOI: 10.5402/2011/194324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
210 Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011;17:440-9. [PMID: 20645317 DOI: 10.1002/ibd.21383] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
211 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 16.1] [Reference Citation Analysis]
212 Mizushima T, Tanida S, Mizoshita T, Hirata Y, Murakami K, Shimura T, Kataoka H, Kamiya T, Joh T. A complicated case of tacrolimus-induced rapid remission after cesarean section in the early third trimester for refractory severe ulcerative colitis flaring in the initial period of gestation. Case Rep Gastroenterol 2011;5:144-51. [PMID: 21552436 DOI: 10.1159/000326938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
213 Hirano K, Maruyama S, Mino Y, Naito T, Kawakami J. Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis. Clinical Biochemistry 2011;44:397-402. [DOI: 10.1016/j.clinbiochem.2010.12.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
214 Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M, Schaeffeler E. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011;89:422-428. [PMID: 21289623 DOI: 10.1038/clpt.2010.348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
215 Nakase H, Yamamoto S, Matsuura M, Chiba T. Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? Aliment Pharmacol Ther 2011;33:413-4; author reply 414-5. [PMID: 21198700 DOI: 10.1111/j.1365-2036.2010.04532.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
216 Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI, Dubinsky M, Alex G, Baldassano RN, Langer JC. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574-588. [PMID: 21224839 DOI: 10.1038/ajg.2010.481] [Cited by in Crossref: 140] [Cited by in F6Publishing: 107] [Article Influence: 12.7] [Reference Citation Analysis]
217 Hart AL, Ng SC. Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? authors’ reply: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;33:414-5. [DOI: 10.1111/j.1365-2036.2010.04539.x] [Reference Citation Analysis]
218 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
219 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
220 Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1(5): 87-93 [PMID: 21577301 DOI: 10.4292/wjgpt.v1.i5.87] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
221 Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010;25:886-891. [PMID: 20546441 DOI: 10.1111/j.1440-1746.2009.06206.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
222 Escher M, Herrlinger K, Stange E. Proktitis – aus gastroenterologischer Sicht. coloproctology 2010;32:267-72. [DOI: 10.1007/s00053-010-0130-7] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
223 Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011;17:22-29. [PMID: 20722055 DOI: 10.1002/ibd.21418] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
224 Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
225 Romano C, Comito D, Famiani A, Fries W. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. Aliment Pharmacol Ther 2010;31:676-7; author reply 677-8. [PMID: 20148798 DOI: 10.1111/j.1365-2036.2009.04213.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
226 Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis--a need for prophylaxis. J Crohns Colitis 2010;4:606-9. [PMID: 21122569 DOI: 10.1016/j.crohns.2010.05.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
227 Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157-165. [PMID: 20227029 DOI: 10.1016/j.bpg.2009.10.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
228 van Lierop PP, de Haar C, Lindenbergh-Kortleve DJ, Simons-Oosterhuis Y, van Rijt LS, Lambrecht BN, Escher JC, Samsom JN, Nieuwenhuis EE. T-cell regulation of neutrophil infiltrate at the early stages of a murine colitis model. Inflamm Bowel Dis 2010;16:442-51. [PMID: 19714763 DOI: 10.1002/ibd.21073] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
229 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
230 Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond). 2010;118:707-715. [PMID: 20350293 DOI: 10.1042/cs20100027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
231 Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346. [PMID: 19637362 DOI: 10.1002/ibd.20997] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 12.5] [Reference Citation Analysis]
232 Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet’s disease. Inflamm Bowel Dis. 2010;16:188-189. [PMID: 19504615 DOI: 10.1002/ibd.20970] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
233 Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, Bretagne JF, Flourié B, Hébuterne X, Bigard MA, Siproudhis L, Peyrin-Biroulet L. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010;31:1178-85. [PMID: 20222911 DOI: 10.1111/j.1365-2036.2010.04293.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
234 Yamamoto S, Nakase H, Chiba T. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis: authors’ reply. Alimentary Pharmacology & Therapeutics 2010;31:677-8. [DOI: 10.1111/j.1365-2036.2009.04224.x] [Reference Citation Analysis]
235 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
236 van Dieren JM, Lambers ME, Kuipers EJ, Samsom JN, van der Woude CJ, Nieuwenhuis EE. Local immune regulation of mucosal inflammation by tacrolimus. Dig Dis Sci. 2010;55:2514-2519. [PMID: 19949865 DOI: 10.1007/s10620-009-1047-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
237 Herrlinger K, Wittig B, Stange EF. [Chronic inflammatory intestinal diseases. Pathophysiology and therapy]. Internist (Berl) 2009;50:1229-46; quiz 1247. [PMID: 19777197 DOI: 10.1007/s00108-009-2485-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935-950. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
239 van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, Nieuwenhuis EE, van der Woude CJ. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009;15:193-198. [PMID: 18825773 DOI: 10.1002/ibd.20644] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
240 Navas López V, Blasco Alonso J, Sierra Salinas C, Barco Gálvez A, Vicioso Recio M. Eficacia y seguridad de tacrolimus oral para el tratamiento de la enfermedad inflamatoria intestinal pediátrica. Anales de Pediatría 2009;70:519-25. [DOI: 10.1016/j.anpedi.2009.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
241 Tung TH. Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery. Hand (N Y) 2010;5:1-8. [PMID: 19363638 DOI: 10.1007/s11552-009-9193-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
242 Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:585-90. [PMID: 19006615 DOI: 10.1007/s11894-008-0106-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
243 Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10 Suppl 3:8-29. [PMID: 18954307 DOI: 10.1111/j.1463-1318.2008.01682.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
244 Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Nakaoka R, Okuyama Y, Oshitani N, Nishishita M, Watanabe K, Fukunaga K, Ohnishi K, Kusaka T, Yokoyama Y, Sasaki M, Tsujikawa T, Aoki T, Kusaka T, Takeda Y, Umehara Y, Nakamura S, Fujiyama Y. Multivariate Analysis for Factors Predicting Rapid Response of Leukocytapheresis in Patients With Steroid-resistant Ulcerative Colitis: A Multicenter Prospective Open-label Study. Therapeutic Apheresis and Dialysis 2008;12:484-90. [DOI: 10.1111/j.1744-9987.2008.00639.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
245 Treton X, Laharie D. Prise en charge d’une colite aiguë grave. Gastroentérologie Clinique et Biologique 2008;32:1030-7. [DOI: 10.1016/j.gcb.2008.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Barrio J, Atienza R, Julián-gómez L, Gil-simón P, García-pajares F, Caro-patón A. Colitis ulcerosa, tacrolimus y curación mucosa. Gastroenterología y Hepatología 2008;31:711-3. [DOI: 10.1016/s0210-5705(08)75825-4] [Reference Citation Analysis]
247 da Luz Moreira A, Vogel JD, Baker M, Mor I, Zhang R, Fazio V. Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis? J Gastrointest Surg 2009;13:504-7. [DOI: 10.1007/s11605-008-0732-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
248 Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, Uza N, Kitamura H, Kasahara K, Chiba T. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn’s disease. J Gastroenterol. 2008;43:774-779. [PMID: 18958546 DOI: 10.1007/s00535-008-2229-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
249 Ng SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008;28:815-29. [DOI: 10.1111/j.1365-2036.2008.03800.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
250 Guthery SL, Dong L, Dean MJ, Holubkov R. US estimates of hospitalized pediatric patients with ulcerative colitis: Implications for multicenter clinical studies: . Inflammatory Bowel Diseases 2008;14:1253-8. [DOI: 10.1002/ibd.20521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
251 Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28:1214-1220. [PMID: 18761706 DOI: 10.1111/j.1365-2036.2008.03841.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
252 Oliva-hemker M, Escher J, Moore D, Dubinksy M, Hildebrand H, Koda Y, Murch S, Sandhu B, Seo J, Tanzi M, Warner B. Refractory Inflammatory Bowel Disease in Children. Journal of Pediatric Gastroenterology & Nutrition 2008;47:266-72. [DOI: 10.1097/mpg.0b013e318181b48c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
253 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
254 Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28:589-597. [PMID: 18549460 DOI: 10.1111/j.1365-2036.2008.03764.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 5.7] [Reference Citation Analysis]
255 Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937-43. [PMID: 18177449 DOI: 10.1111/j.1572-0241.2007.01718.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
256 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
257 Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7-12. [PMID: 17879277 DOI: 10.1002/ibd.20263] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
258 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 147] [Cited by in F6Publishing: 140] [Article Influence: 10.5] [Reference Citation Analysis]
259 Nakamura T, Nagahori M, Kanai T, Watanabe M. Current Pharmacologic Therapies and Emerging Alternatives in the Treatment of Ulcerative Colitis. Digestion 2008;77:36-41. [DOI: 10.1159/000111486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
261 Paclik D, Berndt U, Guzy C, Dankof A, Danese S, Holzloehner P, Rosewicz S, Wiedenmann B, Wittig BM, Dignass AU. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J Mol Med (Berl). 2008;86:1395-1406. [PMID: 18064431 DOI: 10.1007/s00109-007-0290-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
262 Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007;102:2513-9. [PMID: 17680849 DOI: 10.1111/j.1572-0241.2007.01435.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
263 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
264 Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety 2007;6:479-85. [DOI: 10.1517/14740338.6.5.479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
265 Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007;133:1414-1422. [PMID: 17920064 DOI: 10.1053/j.gastro.2007.08.035] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
266 Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a. World J Gastroenterol 2007; 13(26): 3638-3640 [PMID: 17659718 DOI: 10.3748/wjg.v13.i26.3638] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
267 Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:129-134. [PMID: 17206694 DOI: 10.1002/ibd.20052] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
268 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
269 Lal S, Hillary Steinhart A. Infliximab for ulcerative colitis following liver transplantation: . European Journal of Gastroenterology & Hepatology 2007;19:277-80. [DOI: 10.1097/meg.0b013e3280116ccc] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
270 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
271 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
272 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis: EFFICACY AND ENDOSCOPIC PREDICTION OF CYTAPHERESIS THERAPY IN UC. Alimentary Pharmacology & Therapeutics 2006;24:147-52. [DOI: 10.1111/j.1365-2036.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
273 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]